An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate
Clinical high-risk
Conversion to psychosis
Glutamate
Risk calculator
Journal
Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
02
02
2019
revised:
04
09
2019
accepted:
06
09
2019
pubmed:
17
9
2019
medline:
22
6
2021
entrez:
17
9
2019
Statut:
ppublish
Résumé
Risk calculators for prediction of conversion of Clinical High-Risk (CHR) individuals to syndromal psychosis have recently been developed and have generated considerable clinical use and research interest. Predictor variables in these calculators have been clinical rather than biological, and our goal was to incorporate a neurochemical imaging measure into this framework and assess its impact on prediction. We combined striatal glutamate
Identifiants
pubmed: 31522867
pii: S0920-9964(19)30413-X
doi: 10.1016/j.schres.2019.09.004
pmc: PMC7065933
mid: NIHMS1539879
pii:
doi:
Substances chimiques
Glutamic Acid
3KX376GY7L
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
70-73Subventions
Organisme : NIMH NIH HHS
ID : R01 MH110270
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
JAMA Psychiatry. 2019 Feb 1;76(2):115-116
pubmed: 30427988
Biol Psychiatry. 2009 Sep 15;66(6):533-9
pubmed: 19559402
Eur Neuropsychopharmacol. 2015 Oct;25(10):1661-8
pubmed: 26088723
Int J Neuropsychopharmacol. 2015 Sep 12;19(3):pyv105
pubmed: 26364273
Neuropsychopharmacology. 2019 Apr;44(5):907-914
pubmed: 30591713
Am J Psychiatry. 2016 Oct 1;173(10):980-988
pubmed: 27363508
Biol Psychiatry. 2018 Mar 15;83(6):475-483
pubmed: 29132653
Psychiatry Res. 2014 Nov 30;219(3):506-12
pubmed: 25048759
Schizophr Bull. 2014 Sep;40(5):1128-39
pubmed: 24023251
Sci Rep. 2016 Feb 23;6:21873
pubmed: 26903078
Elife. 2018 Sep 27;7:
pubmed: 30260771
Schizophr Bull. 2007 May;33(3):688-702
pubmed: 17440198
Am J Psychiatry. 2018 Sep 1;175(9):915-916
pubmed: 30173550
Int J Neuropsychopharmacol. 2018 Feb 1;21(2):114-119
pubmed: 29020419
Schizophr Bull. 2017 Mar 1;43(2):375-388
pubmed: 27535081
Schizophr Bull. 2003;29(4):703-15
pubmed: 14989408
Schizophr Bull. 2014 Jul;40 Suppl 4:S233-45
pubmed: 24936084
JAMA Psychiatry. 2019 Feb 1;76(2):199-207
pubmed: 30427993
Neuropsychopharmacology. 2011 Aug;36(9):1781-91
pubmed: 21508933
Psychiatry Res. 2017 Nov;257:179-185
pubmed: 28772136
Psychol Med. 2019 May;49(7):1128-1137
pubmed: 29950184
Neuropsychopharmacology. 2014 Nov;39(12):2891-9
pubmed: 24917199
Int J Neuropsychopharmacol. 2013 Mar;16(2):471-5
pubmed: 22717289
JAMA Psychiatry. 2017 Jan 1;74(1):104-106
pubmed: 27851840
Magn Reson Med. 1993 Dec;30(6):672-9
pubmed: 8139448
Neuroimage. 2010 Aug 1;52(1):62-8
pubmed: 20399273
Neuropsychopharmacology. 2018 Jan;43(2):264-271
pubmed: 28745307
JAMA Psychiatry. 2013 Oct;70(10):1057-66
pubmed: 23966023
Neuropsychopharmacology. 2018 Oct;43(11):2249-2255
pubmed: 30087434
JAMA Psychiatry. 2017 May 1;74(5):493-500
pubmed: 28355424